Galectin-3+PD-L1+ CECs identified as immunosuppressive drivers in TNBC
The study identifies Galectin-3+PD-L1+ CD71+ erythroid cells as key immunosuppressive components in triple-negative breast cancer.
Asset / Drug
Drug and asset intelligence for Galectin-3 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.